Furthermore, inhibitors of lysine methyltransferases that target H3K4 like MLL, SMYD and SET7/9 demonstrated antitumor activity in leukaemia, breast cancer and prostate cancer.32 This evidence concerns the gene SETD7 and prostate cancer.